革新的な眼内インプラントを用いたラニビズマブ（Port Delivery Platform with ranibizumab）、国内で医療機器部分の製造販売承認申請
ラニビズマブ（ Port Delivery Platform with ranibizumab ）について、医療機器部分（インプラントおよび付属品）における国内製造販売承認申請を実施 本医療機器承認申...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
ラニビズマブ（ Port Delivery Platform with ranibizumab ）について、医療機器部分（インプラントおよび付属品）における国内製造販売承認申請を実施 本医療機器承認申...
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical News
Scope: Industry
Related coverage
More related coverage
Speeches and presentations
2026 03 24 06 00 00 3260948
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults wit...